Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat for Headache Induction in Healthy Volunteers
NCT05582811Completed
- Sponsor
- Dansk Hovedpinecenter
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of riociguat (3 arms), sponsored by Dansk Hovedpinecenter. Primary endpoint: Change in superficial temporal artery diameter. Started Oct 2022; status: completed.
02
Drugs
riociguat
Beyond the preview
Go deeper on NCT05582811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582811.